Study of Vepugratinib for advanced bladder or urinary tract cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug called Vepugratinib for people with advanced urinary tract cancer that has a specific change in the FGFR3 gene. It may be an option if you haven't had other treatments for advanced cancer and are looking for a new approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic bladder or urinary tract cancer that cannot be removed with surgery
- Your cancer must have a specific change in the FGFR3 gene, found by testing a tumor or blood sample
- You must have measurable disease (tumors that can be tracked with scans)
- You must be able to care for yourself or need only some help (ECOG score 0-2)
- You must not have had any prior systemic treatment (like chemotherapy or immunotherapy) for advanced cancer
- You must have adequate organ function (kidney, liver, blood counts) and no severe eye or nerve problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill, vepugratinib, for people whose cancer has a specific change in a gene called FGFR3. The drug targets this gene change to try to slow or shrink the cancer, and may be an option if standard treatments have not worked.
This trial provides expanded access to vepugratinib, an experimental drug that targets a specific gene change (FGFR3) found in some solid tumors, including bladder cancer. It’s for people who have run out of standard treatment options and cannot join another study of the same drug.
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
This trial tests a new study drug (GB-4362) when added to the usual combination of enfortumab vedotin and pembrolizumab for advanced bladder cancer. It is for people who are about to start this standard treatment and have not had these drugs before.
This trial tests a new drug called vebreltinib combined with standard chemotherapy for advanced non-small cell lung cancer (a common type of lung cancer) in patients whose tumors show high levels of a protein called MET. The goal is to see if this combination can slow cancer growth better than chemotherapy alone.
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
Hear when a new Carcinoma, Transitional Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.